Introduction {#S0001}
============

Hypertension (HTN) is the most prevalent and preventable risk factor for cardiovascular diseases (CVDs) and CVD-related mortality.[@CIT0001] It majorly accounts for global all-cause mortality; 10.5 million deaths in 2016 were related to elevated systolic blood pressure.[@CIT0002],[@CIT0003] The global burden of hypertension data (1990--2015) of population with systolic blood pressure 110--115 mmHg revealed that globally, approximately one in every four adults is suffering from HTN.[@CIT0001] In addition, a survey conducted between 2012 and 2015 showed that in China, 23.2% of total population aged \>18 years had HTN, whereas 41.3% had preHTN.[@CIT0004] Clinical studies have shown that efficient HTN control (\<140/90 mmHg) reduces CVD- and stroke-associated morbidity and mortality.[@CIT0005],[@CIT0006]

Although several classes of antihypertensive (AHT) drugs are available and prescribed as per the guidelines to control HTN,[@CIT0007]--[@CIT0010] their effectiveness is detrimentally affected by poor treatment adherence, which results in increased mortality, cardiovascular morbidity, rate and length of hospitalization, overall medical expenditure, and exacerbated quality of life.[@CIT0011]--[@CIT0014] The World Health Organization defines adherence as "the extent to which a person's behavior---taking medication, following a diet, and/or executing lifestyle changes---corresponds with agreed recommendations from a health-care provider.[@CIT0015]"

Nonadherence to AHT medication has become a global cause of concern as it adversely affects the efforts made by health-care professionals and policy makers to control HTN.[@CIT0016]

Previously, treatment adherence was investigated using pill counts, clinical reports, prescriptions, and patient-reported information.[@CIT0017] However, in recent years, new preferred approaches to measure treatment adherence have been developed, including patient-reported questionnaires, scales, medicine possession ratio (MPR), and proportion of days covered.[@CIT0017] MPR, defined as the percentage/proportion of days' supply obtained until the last refill (refill interval) or a specific time period (fixed refill),[@CIT0018],[@CIT0019] is an established measure of AHT treatment adherence.[@CIT0020]--[@CIT0022] It is generally \<1; however, may exceed 1.0 if the patients obtain refills prior to their supply running out.[@CIT0023] Despite a few limitations (eg, nonavailability of clinical data, etc), pharmacy databases managed by a health-care organization, private as well as government insurance companies serve as a good source of data for evaluating treatment adherence, as they provide "real-world" evidence and the data can be easily retrieved for analysis.[@CIT0018],[@CIT0024]

Several studies have analyzed adherence to AHT drugs in different regions of the world.[@CIT0011],[@CIT0016],[@CIT0025]--[@CIT0028] However, there is scarcity of evidence on AHT treatment adherence among the Chinese population in real-world settings.[@CIT0025],[@CIT0029] Ethnic diversity is reported to affect pharmacological actions of AHT drugs,[@CIT0030] and regional/cultural differences in health care may influence AHT drug-taking behavior of patients with HTN.[@CIT0031] This limits the application of treatment adherence information of one geographical region to another in true sense. Therefore, we evaluated AHT treatment adherence, in terms of MPR, and the factors affecting MPR of the seven most commonly used AHT drugs among the Chinese population in real-life settings using information extracted from the China Health Insurance Association (CHIRA) database.

Methods {#S0002}
=======

Study Design {#S0002-S2001}
------------

This was a retrospective analysis of data of patients with HTN taken from the CHIRA database for 2014. The CHIRA database had data of 6,560,000 patients from 77 cities, of which, data of 3,344,000 patients were excluded due to lower/missing outpatient diagnosis rate and/or higher diagnosis missing rate ([Figure 1](#F0001){ref-type="fig"}). Employee medical insurance data of 33 cities with relatively high quality (including outpatient and inpatient data) were used for the analysis.Figure 1Study flow diagram.

Patients with clinically diagnosed HTN and aged ≥18 years were included in the analysis if their first prescription for 2014 had any of the following AHT drugs: benazepril, an angiotensin-converting enzyme (ACE) inhibitor; valsartan, an angiotensin receptor blocker (ARB); metoprolol, a β-blocker; nifedipine and nifedipine gastrointestinal tablets (GITs), a calcium channel blocker (CCB); amlodipine, a CCB; indapamide, a diuretic; or valsartan/amlodipine fixed-dose combination (FDC). Patients covered by employee medical insurance and patients with hypertension caused by secondary diagnosis were also included in the study. Of these patients, only those who were prescribed AHT drugs at least or more than twice were observed for ≥180 days (first prescription-last prescription) were included in the analysis. Patients with cancer, organ failure, and gestational/postoperative HTN were excluded from the analysis. The successive prescriptions were used to analyze treatment adherence. During the data extraction step, data on member eligibility (demographics); inpatient medical information---admission date/discharge date; place of service including hospital tier (tier 1, primary care hospitals; tier 2, city-level hospitals; tier 3, teaching hospitals); type, and department; length of stay; primary diagnosis according to International Classification of Disease (ICD)-10/Chinese texts; and diagnosis description); and outpatient medical information---date; place of service including hospital tier; type, and department; and primary diagnosis (ICD-10/Chinese text); services claims (drug name, drug code; prescription, examination, treatment, operation, bed, medical materials, etc; drug unit price; drug formulations; and dispensed quantity of drug), cost of each event, and other relevant information was extracted. The data for cities with outpatient diagnosis missing rate of ≥90%, hospital diagnosis missing rate of ≥20%, and the ratio of outpatients number to inpatients number is ≥5. After excluding patients other than those with ICD 10 I10--115 HTN, patients with organ failure and/or cancer and/or gestational/postoperative HTN, 64,576 patients (mean age: 63.4 years; males: 51.73%; females: 48.27%) were included in the analysis.

The study was conducted in accordance with the Guidelines for Good Pharmacoepidemiology Practice,[@CIT0032] Good Practice of Secondary Data Analysis,[@CIT0033] the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance Guideline on Methodological Standards in Pharmacoepidemiology,[@CIT0034] and Good Epidemiological Practice.[@CIT0035]

End Points {#S0002-S2002}
----------

Measuring treatment adherence among study populations in terms of MPR was the primary end point of the study. The secondary end points were hospital visits and determination of the factors affecting treatment adherence.

For 2014, MPR was calculated as total days' supply of drug dispensed (excluding the last prescription) during the year divided by total days from the first prescription until the last prescription given during the observation period. Total drug supply for each study drug was calculated as the total amount of drug prescribed in 2014 divided by defined daily dose. Observation period was taken as the period between the first claim records with HTN and the last claim records due to any reason in 2014.

MPR of the seven AHT drugs was calculated for three different time periods: (1) the first study drug prescription to the last study drug prescription (drug in the first and last prescription need not be same), that is, the first goal (FG) to the last goal (LG); (2) the first study drug prescription to the last other AHT drug (an AHT drug that is not included in this study) prescription, that is, FG to the last random (LR); and (3) the first other AHT drug prescription to the last other AHT drug prescription, that is, the first random (FR) to LR. Treatment adherence was considered very low, low, intermediate, and high corresponding to MPR values \<0.3, 0.3 to \<0.5, 0.5 to \<0.8, and ≥0.8, respectively.[@CIT0012],[@CIT0036]

Statistical Analysis {#S0002-S2003}
--------------------

All the analyses were performed using statistical analysis software (SAS) 9.3 version. Descriptive analysis was used for continuous variables: mean, SD, standard error (SE) and categorical variables: frequency tables: absolute and relative frequencies. MPR for FG-LR was categorized in ranges of 0≤MPR\<0.3, 0.3≤MPR\<0.5, 0.5≤MPR\<0.8, and 0.8≤MPR\<1. MPR was analyzed using descriptive statistics, whereas factors affecting MPR were analyzed using multivariate regression analysis. Analysis of covariance was used to evaluate variation in MPR values among AHT drugs. *P*-value of \<0.05 was considered significant.

Results {#S0003}
=======

Study Population {#S0003-S2001}
----------------

Out of 64,576 patients included in the analysis, the proportion of patients in \>40, 40--59, 60--79, and ≥80-year age group was 3.3%, 35.14%, 50.65%, and 10.98%, respectively. Eastern, midland, and western regions contributed 89.46%, 3.95%, and 6.59% of the study population. Of the included patients, 46.19% were from municipalities and 36.80% were from provincial capitals. The average observation duration was 290 days for all the study drugs.

[Table 1](#T0001){ref-type="table"} presents baseline characteristics and demographics data of patients with HTN for individual AHT drug included. The highest number of patients were receiving amlodipine (33.98%), whereas the least number of patients were taking valsartan/amlodipine FDC (1.60%). Patients receiving metoprolol were the oldest among all groups (mean age, 64.85 years). Comorbidities were present in 63.01% of the patients included in the analysis with highest proportion observed in patients receiving nifedipine GITs (76.14%) and lowest among those receiving amlodipine (53.09%).Table 1Baseline and Comorbidity Characteristics of Different Antihypertensive DrugsBenazeprilNifedipine GITsAmlodipineMetoprololValsartanIndapamideValsartan/AmlodipineNo. of patients (N)377811,07721,94516,170891016611035Primary diagnosis with HTN (% of n)Patients with primary HTN96.4897.7397.0296.5697.0396.6395.46Patients with secondary HTN1.110.482.092.121.541.513.48Secondary diagnosis with HTN (% of N)2.411.790.891.321.431.861.06Mean observation duration (days)291.56295.45290.55293.65291.38293.65289.25Men (% of N)55.1150.7549.4550.9650.6252.6852.56Women (% of N)44.8949.2550.5549.0449.3847.3247.44Mean age (years)63.1263.0863.8064.8562.4464.2162.29\*Comorbidities (% of N)66.9176.1453.0964.8563.4556.3560.29 Coronary heart disease48.9160.9635.7752.5845.4440.2839.23 Diabetes mellitus39.8943.8327.8628.6735.1631.1332.75 Stroke13.7617.5810.7611.6811.9512.5211.79 Chronic renal diseases3.263.852.242.543.311.694.35 Peripheral vascular disease0.821.270.520.720.790.660.97[^1][^2]

MPR of AHT Drugs {#S0003-S2002}
----------------

Among all the analysis groups, nifedipine GITs treatment was associated with the highest mean MPR (0.61), whereas metoprolol had the lowest (0.19). MPR values of the study AHT drugs are given in [Figure 2A](#F0002){ref-type="fig"}. The difference observed in the mean MPR values for different AHT drugs was significant (*P*\<0.0001). MPR of AHT drugs based on gender, age, city level, hospital tiers, comorbidities, and hospitalization status are presented in the [[Supplementary Table](https://www.dovepress.com/get_supplementary_file.php?f=243665.docx)]{.ul}.Figure 2MPR of different AHT drugs. (**A**) Mean MPR values; (**B**) percentage of population with MPR of ≥0.5; (**C**) population distribution among different range of MPR of AHT drugs. The difference among groups was statistically significant for mean MPR and proportion of patients with ≥0.5 MPR (*P*\<0.0001 for both).**Abbreviations:** MPR, medicine possession ratio; GITs, gastrointestinal tablets.

The proportions of patients with ≥0.5 MPR were shown in [Figure 2B](#F0002){ref-type="fig"}. Nifedipine GITs-treated patients had the highest proportion of MPR ≥0.5 (60.44%); whereas metoprolol-treated patients had the least proportion (11.31%). Metoprolol group had highest proportion of patients with very low treatment adherence, ie, MPR \<0.3 (78.21%), whereas nifedipine had highest proportion of patients with high treatment adherence, ie, MPR ≥0.8 (40.85%), as depicted in [Figure 2C](#F0002){ref-type="fig"}.

Use of AHT Drugs {#S0003-S2003}
----------------

The proportion of patients receiving combination of AHT drugs was 56.27%. Among the patients included in the study, 60.86% had replacement of study drug during the observation period. The data of AHT drug usage among the study population and the associated daily cost are provided in [Table 2](#T0002){ref-type="table"}. Proportion of patients switching to an AHT drug other than those included in this study was least in valsartan/amlodipine FDC group (30.14%) and highest in metoprolol group (46.00%), ([Table 2](#T0002){ref-type="table"}). Among AHT drugs, indapamide had the least daily cost (0.93 yuan), whereas valsartan/amlodipine FDC had the highest daily cost (8.7 yuan).Table 2The Use of the Seven Antihypertensive Drugs Among the PatientsVariablesBenazepril\
N=3778Nifedipine GITs\
N=11,077Amlodipine\
N=21,945Metoprolol\
N=16,170Valsartan\
N=8910Indapamide\
N=1661Valsartan/amlodipine\
N=1035Proportion of multidrug combination in the first prescription (%)61.8346.0651.5268.9257.1268.2740.19Proportion of drug replacement (%)62.0761.9451.2963.5261.2877.5448.41 Switching to benazepril (%)--3.772.212.031.761.930.77 Switching to nifedipine controlled release tablets (%)9.95--3.806.649.586.262.51 Switching to amlodipine (%)11.917.39--11.2112.2910.0510.63 Switching to metoprolol (%)9.568.878.28--8.739.399.47 Switching to valsartan (%)5.118.015.125.05--5.548.70 Switching to indapamide (%)1.481.270.871.060--.94--1.06 Switching to valsartan/amlodipine (%)0.000.500.760.761.040.84-- Switching to antihypertensive drug(s) other than the seven target drugs (%)37.5342.1338.6146.0038.8743.5330.14Daily cost of antihypertensive drugs (yuan) (%)7.814.494.384.004.400.938.70[^3]

Outpatient Visit {#S0003-S2004}
----------------

The number of annual per capita outpatient visit was highest for Nifedipine GITs (32.6) and lowest for valsartan/amlodipine FDC (19.73). Approximately 45.02% of patients with HTN visited the tier 1 hospitals and grass-root community units followed by tier 3 hospitals (35.82%), tier 2 hospitals (16.58%), and pharmacies (2.44%), with 0.14% of patients visiting unknown medical institutions. [Table 3](#T0003){ref-type="table"} presents hospital visit data of patients as per the prescribed AHT drug.Table 3Hospital Visits by Patients Receiving Studied AHT DrugsBenazeprilNifedipine GITsAmlodipineMetoprololValsartanIndapamideValsartan/amlodipine**Annual per capita outpatient visit (mean)**27.2132.6022.1124.7927.3825.0419.73**Annual per capita hospital admission (mean)**0.490.390.380.550.370.480.32**Direction of outpatient flow (%)** Tier 3 hospitals31.9631.0332.2436.0832.7129.3857.32 Tier 2 hospitals16.8015.3415.7318.0515.5219.2015.43 Tier 1 hospitals48.2650.9649.5942.5749.3648.3226.11 Pharmacies2.882.532.263.062.302.921.11 Others0.100.140.180.230.110.180.03**Direction of inpatient flow (%)** Tier 3 hospitals54.0459.9756.1056.6858.5650.2577.98 Tier 2 hospitals27.0825.6828.8332.3126.2232.1315.90 Tier 1 hospitals18.1813.9413.449.7913.6015.885.50 Others0.710.411.631.221.621.750.61[^4]

Potential Factors Affecting MPR of AHT Drugs {#S0003-S2005}
--------------------------------------------

Factors that could have modulated MPR were evaluated using stepwise regression based on a multivariate linear regression model. The results showed that MPR was positively affected (*P*\<0.0001 for all comparisons) by following variables: (1) age, (2) city level, (3) comorbidities (diabetes, stroke), (4) prescription of multidrug combination, (5) tier 3 hospital visits, (6) reimbursement ratio, (7) study drugs, except metoprolol, in the first prescription ([Table 4](#T0004){ref-type="table"}). Presence of coronary artery disease (SE, 0.003; *P*=0.0016), times of hospitalization (SE, 0.0030; *P*\<0.0001), and metoprolol prescription (SE, 0.0068; *P*\<0.0001) negatively affected MPR ([Table 4](#T0004){ref-type="table"}).Table 4Factors Affecting MPR. Results of Multivariate Regression AnalysisVariablesParameter estimationStandard errorT valueP-valueGender (male patients as control)−0.00460.0024−1.90.0573Age (≤40 years as control) 41--60 years0.07760.006811.44\<0.0001 61--80 years0.09990.006814.73\<0.0001 ≥81 years0.09120.007811.75\<0.0001City level (prefecture level as control) Municipalities0.07460.004217.72\<0.0001 Provincial capital0.00400.00430.930.3516Comorbidities Diabetes0.03300.002712.18\<0.0001 Stroke0.01120.00382.920.0035 Coronary artery disease−0.00950.0030−3.150.0016 Chronic renal diseases0.01340.00741.810.0701 Peripheral vascular diseases0.02150.01411.520.1290 Multidrug combination vs monotherapy0.02210.00297.7\<0.0001 Visit to tertiary hospital0.08210.003126.05\<0.0001 Number of hospitalizations−0.04020.0030−13.4\<0.0001 Average reimbursement ratio0.11510.004227.05\<0.0001Drug in the first prescription (benazepril alone as control) Nifedipine GITs0.28290.006941.05\<0.0001 Amlodipine0.13590.006520.78\<0.0001 Metoprolol−0.11260.0068−16.46\<0.0001 Valsartan0.25530.007235.38\<0.0001 Indapamide0.10240.01099.41\<0.0001 Valsartan/amlodipine FDC0.23270.011819.74\<0.0001 Combination of two or more drugs0.28250.007338.42\<0.0001[^5]

Discussion {#S0004}
==========

Research on AHT treatment adherence helps understanding the current scenario of treatment adherence, designing interventions, and formulating relevant policies to improve the health outcomes of patients. To the best of our knowledge, this is the first large-scale study to determine treatment adherence for different AHT drugs in China using the CHIRA database. Given the fact that treatment adherence is influenced by demographic, region-specific, organizational, comorbidities, and medication-related variables, we also investigated the association of these factors with the recorded MPR for all AHT drugs included in the study. Our results showed poor overall AHT treatment adherence among Chinese patients with HTN and revealed that they have the highest treatment adherence for nifedipine GITs and the lowest for metoprolol. A positive association of MPR with age, city level, comorbidities, frequency of outpatient visits, and hospitalization was observed.

We used the MPR to evaluate treatment adherence among the study population, which is a globally accepted metric to retrospectively assess treatment adherence.[@CIT0018],[@CIT0037] Other measures of treatment adherence include medication-total, adherence ratio, proportion of days covered, refill adherence, compliance rate, compliance ratio, continuous measure of medication acquisition, continuous measure of medication gaps, continuous/single interval measure of medication acquisition, and continuous/single interval measure of medication gaps.[@CIT0019] However, MPR is the most commonly used measure of treatment adherence.[@CIT0018] MPR is used as a continuous variable or with appropriate justification, as a dichotomized variable.[@CIT0018] However, it does not take gaps in refills into account and heavily depends on the denominator used during calculations (either number of days elapsed during the period or total study duration).[@CIT0037] Hence, the MPR is not useful to evaluate nonadherence in case of premature terminations and gap in refilling.[@CIT0037] In spite of these limitations, MPR has been used in various studies to assess treatment adherence as it is easy to calculate and interpret.[@CIT0018],[@CIT0019] Previous studies have shown that the type of AHT drug prescribed significantly affects treatment adherence and persistence.[@CIT0038]--[@CIT0043] Among AHT agents, ACE inhibitors and CCBs are reported to have better treatment adherence and persistence compared with diuretics and β-blockers.[@CIT0038]--[@CIT0043] In a study carried out in Italian patients with HTN, it revealed a higher continuation rate in patients treated with ACE inhibitors (23.2%), ARBs (25.2%), and CCBs (23.9%) than in those treated with β-blockers and diuretics (11.2--11.8%).[@CIT0039] Mancia et al have reported that the risk of discontinuation of AHT treatment was the lowest for ARBs (HR, 0.3; 95%CI, 0.29-- 0.30\], followed by ACE inhibitors (HR, 0.35; 95%CI, 0.51-- 0.53), CCBs (HR, 0.52; 95%CI, 0.51-- 0.53), and β-blockers (HR, 0.5; 95%CI, 0.53-- 0.55) compared with diuretics.[@CIT0044] Our results showing the highest treatment adherence for nifedipine GITs, and least treatment adherence for metoprolol, are in line with these previous observations.

Although replacement rate of drug was high in the indapamide group, treatment adherence for it was comparable to other classes of AHT drugs ([Figure 2A--C](#F0002){ref-type="fig"}). This is in contrast with the findings of Schulz et al, who reported the highest nonadherence for diuretics (66.3%) and the lowest for β-blockers (55.2%).[@CIT0022] We speculate lower daily cost for indapamide treatment might have positively affected the adherence of patients with HTN to it.

In addition, our results showed that treatment adherence for AHT drugs is significantly affected by the level of the city with better adherence observed in patients receiving treatment in municipalities. The impact of city level on patients' adherence might be due to cost-efficient management services provided including health records, regular follow-ups and health education[@CIT0045],[@CIT0046] as reported by a survey showing significant association between community management and AHT treatment adherence.[@CIT0047] Furthermore, in our study, older age and presence of comorbidity positively affected treatment adherence, which is in line with the results of a study by Schulz et al showing lower nonadherence to AHT drugs in older patients (aged ≥65 years) than younger patients,[@CIT0022] and other studies.[@CIT0048],[@CIT0049] This highlights the need to improve health care for the younger population. In addition, our study showed lower adherence of females to treatment which is in contrast with the findings of Wong et al.[@CIT0029] Results from the China Health and Nutrition survey, which reported increased chances of receiving treatment (28.7%; 95%CI, 10.6-- 46.7) among patients with health insurance also support our results showing the positive effect of the reimbursement ratio on AHT drug compliance.[@CIT0050]

The strength of our study lies in the use of real-world data for the analysis, large sample size, and the accuracy of information available in the CHIRA database.

Our study had a few limitations. First, this was a retrospective study and so there are chances of bias in data selection and analysis. Second, the duration of this study was short, ie, one year due to which the treatment adherence observed could be higher than that of a study with longer duration. Third, 91.5% of the population included in the analysis was from the eastern region of China. Hence, the generalizability of these results to patients from central and western regions of China is limited. The analysis of treatment adherence was based on prescription information, and therefore, whether the drugs prescribed were consumed or not by the patients stays unclear. Hence, results should be interpreted carefully as there are chances of under- or overestimation of treatment adherence. Fourth, we could not evaluate the effect of treatment adherence on blood pressure control rate and health outcomes as the CHIRA database did not reflect information in this regard. Fifth, DDD was not suitable for MPR estimation of β-blockers. Finally, we did not examine other factors that can influence treatment adherence, such as social support, socioeconomic status of patients, and reminders for medicine intake.

Conclusion {#S0005}
==========

Our results showed poor overall AHT treatment adherence among Chinese patients with HTN. Better reimbursement ratio, use of combination therapy and prescribing effective long-acting AHT drugs will help to improve treatment adherence, and hence HTN management, in China.
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[^1]: **Note:** \*Some patients have more than one comorbidity.

[^2]: **Abbreviations:** HTN, hypertension; GITs, gastrointestinal tablets.

[^3]: **Abbreviation:** GITs, gastrointestinal tablets.

[^4]: **Abbreviation:** GITs, gastrointestinal tablets.

[^5]: **Abbreviations:** FDC, fixed-dose combination; GITs, gastrointestinal tablets.
